Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses

被引：60

作者：

Wu, JJ

Huang, DB

Tyring, SK ^{[1
]}

机构：

[1] Univ Texas, Hlth Sci Ctr, Dept Dermatol, Houston, TX USA

[2] Univ Calif Irvine, Dept Dermatol, Irvine, CA 92717 USA

[3] Baylor Coll Med, Dept Med, Div Infect Dis, Houston, TX USA

[4] Univ Texas, Sch Publ Hlth, Ctr Hlth Sci, Houston, TX USA

[5] Univ Texas, Hlth Sci Ctr, Dept Med, Div Infect Dis, Houston, TX USA

[6] Ctr Clin Studies, Houston, TX USA

来源：

ANTIVIRAL RESEARCH | 2004年 / 64卷 / 02期

关键词：

resiquimod; immunomodulation; genital herpes; herpes simplex virus type 2;

D O I：

10.1016/j.antiviral.2004.07.002

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Genital herpes is one of the most common sexually transmitted diseases worldwide. Currently, there are three FDA-approved nucleotide analogs and other therapies such as foscarnet and cidofovir used to treat genital herpes. Resiquimod, the latest immune response modifier (IRM), has shown in vivo evidence of efficacy against herpes simplex virus (HSV) type 2. The first clinical trial involving resiquimod demonstrated that it reduced the recurrence rate of genital herpes, but phase III trials were suspended due to lack of efficacy. Resiquimod shows promise for other viral infections and as a vaccine adjuvant. (C) 2004 Elsevier B.V. All rights reserved.

引用

页码：79 / 83

页数：5

共 50 条

[1]

Abramovits William, 2004, Skinmed, V3, P215

[2] Dendritic cell maturation and subsequent enhanced T-cell stimulation induced with the novel synthetic immune response modifier R-848 [J].